Objectives: To determine the prevalent age of symptomatic benign prostate hyperplasia (BPH), the average BPH volume, and the association between BPH volumes and the age, and anthropometrics in our immediate black community.
Patients, Materials And Method: Selected patients with lower urinary tract symptoms (LUTS) due to BPH with tissue diagnosis, and adult men of similar age group with no irritative or obstructive LUTS were prospectively studied from July 2003 to June 2009. The age, height and weight were recorded, prostate volumes determined with ultrasound, body mass index (bmi) calculated, and correlations determined between the prostate volume and the age, and anthropometrics.
Results: 105 patients aged 43-88 yrs (mean=64.4, 8.88 SD) managed for BPH were studied with 93 asymptomatic men aged 43-80 yrs (mean=56.15, 9.89 SD). The mean (SD) prostate volume, height, weight and bmi were 83.8 (37.7) ml, 1.67 (0.07) m, 63.6 (9.32) kg and 22.8 (3.03) kg/m2, and 24.5 (9.2) ml, 1.69 (0.06) m, 68.9 (10.6) kg and 24.2 (3.44) kg/m2 respectively for symptomatic and asymptomatic groups. In the symptomatic group, BPH volume showed significant positive correlation with the age (p=0.030), but no correlation with the weight (p=0.550), height (p=0.375) and bmi (p=0.840). In the asymptomatic group, prostate volume also showed significant positive correlation with the age (p=0.041), but no correlation with the weight (p=0.434), height (p=0.394), and bmi (p=0.203).
Conclusion: The prevalent age of symptomatic BPH in our community is 43- 88 years with 83.79 (37.66) ml mean (SD) volume in symptomatic patients and 24.45 (9.21) ml in asymptomatic men. BPH volume correlates with age but not with anthropometrics. Lack of correlation with BPH volume suggests that anthropometrics may not be risk factors for development of BPH in our community.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Robotic Waterjet Resection for Men with Prostate Cancer Suffering from Lower Urinary Tract Symptoms.
Urology
January 2025
S.H. Ho Urology Centre, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Objectives: To evaluate the impact of Aquablation on circulating tumor cells (CTCs) in men with localized prostate cancer.
Methods: This prospective study included subjects with biopsy-positive mpMRI visible lesions (PIRADS ≥ 3) who underwent Aquablation. Ten ml blood samples were collected before, during and after the procedure to measure CTC counts using an immunofluorescence assay.
SPOP enhances FADD degradation and decreases the activeness of the NF-κB signaling pathway in prostate cancer: an study.
Transl Androl Urol
December 2024
Department of Urology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, China.
Background: Speckle-type POZ protein (SPOP), FAS-associated protein with death domain (FADD), and nuclear transcription factor-κB (NF-κB) have been shown to be associated with the development of prostate cancer (PCa). FADD has been shown to activate the NF-κB pathway to promote tumorigenesis, while SPOP has been shown to enhance the breakdown of FADD and inhibit the function of the NF-κB signaling pathway in non-small cell lung cancer. The existence of this mechanism has not yet been confirmed in PCa.
View Article and Find Full Text PDFWater vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).
World J Urol
January 2025
Department of Urology, AP-HM, North Hospital, Marseille, France.
Introduction: Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.
View Article and Find Full Text PDFEfficacy and safety of oral Chinese patent medicine for benign prostatic hyperplasia: a network meta-analysis of randomized controlled trials.
Front Med (Lausanne)
December 2024
Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Objective: This paper aims to evaluate the disparities in efficacy and safety across various oral Chinese patent medicines for the treatment of benign prostatic hyperplasia (BPH), using a frequency-based reticulated meta-analysis.
Methods: The researchers searched the following databases: Web of Science, PubMed, Excerpta Medical Database (Embase), Cochrane Library, China Knowledge Network (CNKI), China Biomedical Literature Service System (SinoMed), Wanfang Data Knowledge Service Platform and China Science and Technology Periodicals Database (VIP). Besides, the researchers collected all randomized controlled trials (RCTs) of oral Chinese patent medicines, as well as simple preparations and simple preparations for benign prostatic hyperplasia from the establishment of the database until July1, 2024.
MRI-Derived Transition Zone Index Is Highly Predictive of Urodynamic Bladder Outlet Obstruction Prior to Holmium Laser Enucleation of the Prostate.
Neurourol Urodyn
January 2025
Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Introduction And Objective: Urodynamic study (UDS) is required to diagnose bladder outlet obstruction (BOO) during evaluation of benign prostatic hyperplasia (BPH) but is seldom performed due to cost and invasiveness. Therefore, anatomic and clinical parameters to predict BOO have been proposed, including the prostate transition zone index (TZI) which is the ratio of prostate transition zone volume (TZV) to whole gland volume (WGV). Historically computed with ellipsoid volume estimation of prostate WGV and TZV from transrectal ultrasound measurements, controversy exists regarding the utility of TZI to predict likelihood of BOO on UDS and clinical outcomes following BPH surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!